Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine Rollover Study in Pediatric Tourette Syndrome
NCT03732534Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of valbenazine in Tourette syndrome (TS), sponsored by Neurocrine Biosciences. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 16 weeks. Started Oct 2018; status: terminated.
02
Drugs
valbenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT03732534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732534.